Inactive Instrument

All News Ibere Pharmaceuticals

Equities

Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Ibere Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Ibere Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Ibere Pharmaceuticals Auditor Raises 'Going Concern' Doubt	22-03-30	CI
Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Certain Class B Ordinary Shares of Ibere Pharmaceuticals are subject to a Lock-Up Agreement Ending on 24-AUG-2021.	21-08-23	CI
Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Ibere Pharmaceuticals : Letter dated August 4, 2021 from Marcum LLP (Form 8-K)	21-08-04	PU
Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report	21-05-28	PR
Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report (Form 8-K)	21-05-28	PU
Ibere Pharmaceuticals announced that it has received $4.835 million in funding	21-03-01	CI
Ibere Pharmaceuticals has completed an IPO in the amount of $120 million.	21-02-26	CI
Ibere Pharmaceuticals announced that it expects to receive $4.835 million in funding	21-02-24	CI
Ibere Pharmaceuticals has filed an IPO in the amount of $100 million.	21-02-08	CI

No results for this search